PepGen Inc.
PEPG
$0.09
Change (1 day)
$19.30
Year High
$4.00
Year Low
Categories
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
PepGen Inc. (PEPG) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -60,670,000 | 34.63 M | 143.05 M | 112.68 M | |
| 2022 | 58 K | -157,218,000 | 37.81 M | 217.44 M | 186.08 M |
| 2021 | 4.74 M | -132,895,000 | 10.55 M | 143.64 M | 139.99 M |
| 2020 | 407 K | -9,778,000 | 868 K | 10.64 M | 10.32 M |
| 2019 | 230 K | -3,491,000 | 326 K | 4.19 M | 3.77 M |